Biotech Valuations 2025: Rational Reset or Overlooked Rebound?
As we find ourselves in mid-2025, biotech stocks are echoing the tempered days of 2018, sitting at around 50% below their 2021 highs. This recalibration raises a vital question: are...
Thematic Focus
1932 results found
Exploring Regeneron Pharmaceuticals: Is $REGN a Hidden Gem or Just...
Regeneron Pharmaceuticals, a biotech behemoth, has seen a dramatic 60% drop from its peak valuation of $120 billion, presenting a tantalising dilemma for investors: disaster or opportunity? With strong fundamentals...
Biotech’s Lost Decade: Exploring a Thematic Transformation and Future Prospects
Biotech, traditionally a powerhouse of innovation, has been stuck in an unexpected rut for nearly a decade, lagging behind broader market progress. Despite groundbreaking advancements in gene editing and personalised...
Biotech Blues: Unravelling the Surge in Negative Enterprise Value
A remarkable 23% of biotech companies are now trading with negative enterprise values, signalling profound investor scepticism. This condition suggests a sector-wide crisis of confidence, with implications ranging from M&A...
Biotech Revolution: Unveiling the Future of mRNA, CRISPR, RNAi, and...
Biotechnology strides swiftly ahead, offering groundbreaking innovations like mRNA vaccines and CRISPR therapies that are transforming healthcare and investment strategies. The sector's explosive growth, powered by RNAi and CAR-T advancements,...
Investor Sentiment and the Innovation Paradox: Navigating Opportunities in 2025
As investor sentiment remains sluggish in mid-2025, the market is drowning in innovation yet lacking a unifying focus. This paradox of ingenuity and apathy offers a unique opportunity for contrarians,...
Will Ageing Demographics Spur Demand for New Therapies in Healthcare...
As the global population ages at an unprecedented rate, the demand for innovative medical therapies is set to surge, challenging industries to adapt. By 2030, one in six people will...
Pharmaceuticals in Peril: Navigating the Impact of Proposed Drug Price...
The pharmaceutical industry stands at a crossroads as governments worldwide push for dramatic prescription drug price cuts. With major legislation like the Inflation Reduction Act targeting cost reductions, even the...
Google’s AI Workloads: A Ninefold Surge in Inference Tokens
Google's AI workloads have soared dramatically, with inference tokens skyrocketing from 71 trillion to 634 trillion in less than a year. This astonishing growth signals a transformative shift in AI...
The $IREN Dilemma: Chasing Dreams at Sweetwater with Slim Pockets
Iris Energy's ambitious Sweetwater project in Texas presents a staggering $70 billion funding challenge against a mere $200 million cash reserve. As they pivot towards AI and HPC infrastructure alongside...
